Table 1.
Clinical data on the 21 patients who participated in the study
| Patient | Lesioned side | Lesion location | Age (years) | Sex | Diagnosis | Handedness | Date of surgery |
|---|---|---|---|---|---|---|---|
| PAT01 | left | ST | 40 | male | arteriovenous malformation | left | 01.05.1991 |
| PAT02 | left | ST | 52 | male | cavernous angioma | right | 01.11.1990 |
| PAT03 | left | ST | 53 | female | cavernous angioma | right | 01.08.1990 |
| PAT04 | left | ST | 37 | female | cavernous angioma | right | 17.10.1989 |
| PAT05 | left | ST | 42 | male | cavernous angioma | left | 24.05.1992 |
| PAT06 | left | ST | 45 | female | cavernous angioma | right | 25.04.1994 |
| PAT07 | left | ST | 45 | female | cavernous angioma | right | 28.07.1994 |
| PAT08 | right | ST | 54 | female | ischemic infarction | right | • |
| PAT09 | right | ST | 54 | male | cavernous angioma | right | 09.11.1993 |
| PAT10 | right | ST | 27 | male | arteriovenous malformation | right | 05.10.1993 |
| PAT11 | right | ST | 35 | male | arteriovenous malformation | right | 01.12.1995 |
| PAT12 | left | LIP | 32 | male | arteriovenous malformation | right | 13.03.1991 |
| PAT13 | left | LIP | 31 | female | arteriovenous malformation | right | 06.12.1991 |
| PAT14 | right | LIP | 32 | male | cavernous angioma | left | 01.05.1993 |
| PAT15 | right | LIP | 56 | female | meningioma | right | 05.02.1989 |
| PAT16 | left | IT | 26 | female | cavernous angioma | right | 01.05.1993 |
| PAT17 | left | IT | 33 | female | astrocytoma | right | 03.01.1992 |
| PAT18 | left | IT | 46 | male | cavernous angioma | right | 15.02.1995 |
| PAT19 | right | IT | 30 | male | meningioma | right | 01.02.1991 |
| PAT20 | right | IT | 41 | female | cavernous angioma | right | 01.11.1986 |
| PAT21 | right | IT | 42 | female | astrocytoma | right | 07.05.1990 |
| Months since surgery | Symptoms before surgery | Symptoms at time of study | Medication (possibly sedative) at time of study | ||||
| 37 | lower right quadrant defect for small targets | lower right quadrant defect for small targets | none | ||||
| 44 | 2× GM | none | none | ||||
| 47 | GM, partial complex seizures, mild aphasia | none | phenytoin 500 mg | ||||
| 57 | none | ||||||
| 28 | 1× GM | none | carbamazepine 400 mg | ||||
| 17 | headache, impaired vigilance, short-term memory disorder | headache, short-term memory disorder | carbamazepine 1200 mg | ||||
| 15 | generalized seizures | carbamazepine 200 mg | |||||
| • | none | none | none | ||||
| 10 | 1× GM | none | carbamazepine 400 mg | ||||
| 24 | several GM, lower left visual quadrant defect | left hemiparesis, lower left visual quadrant defect | phenytoin 800 mg | ||||
| 0 | 1× GM | none | carbamazepine 800 mg | ||||
| 40 | 1× GM | none | none | ||||
| 50 | mild aphasia, hemiparesis right | mild aphasia, right hemiparesis | carbamazepine 400 mg | ||||
| 16 | 3× GM | none | carbamazepine 400 mg | ||||
| 80 | hypaesthesia in left lower limb | none | none | ||||
| 13 | severe headache | none | none | ||||
| 32 | partial seizures | none | none | ||||
| 8 | partial seizures, 1× GM | none | carbamazepine 400 mg | ||||
| 28 | lower left quadrant defect for small targets | lower lower quadrant defect for small targets | none | ||||
| 94 | several seizures | none | none | ||||
| 49 | 1× GM | none | carbamazepine 900 mg |
GM, Grand mal seizure; ST, superior temporal; IT, inferotemporal; LIP, lateral inferoparietal. Table 1 continues.